A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling

Conclusion: Promotion of AR, in addition to enhancement of the Akt-, NFkappaB-, and Hh-pathways by sustained MID1-upregulation during androgen deprivation therapy provides a powerful proliferative scenario for PCa progression into castration resistance. Thus MID1 represents a novel, multi-faceted player in PCa and a promising target to treat castration resistant prostate cancer.

http://www.molecular-cancer.com/content/13/1/146

Source: Molecular Cancer - June 9, 2014 Category: Cancer & Oncology Authors: Andrea KöhlerÜmmühan DemirEva KicksteinSybille KraussJohanna AignerBeatriz Aranda-OrgillésAntonios KaragiannidisClemens AchmüllerHuajie BuAndrea WunderlichMichal-Ruth SchweigerGeorg SchaeferSusann SchweigerHelmut KlockerRainer Schneider Source Type: research